Mankind Pharma Ltd (MANKIND) Q1FY27 Management Mirror - Jun-2026 Qtr
Jun'26 Qtr EBITDA Margin Reported at 26.2%; FY27 Guidance Reaffirmed at 25.5%-26.5% Amid Commodity Cost Pressures
Management's current expectation for FY27 EBITDA margin is 25.5% to 26.5%, with gross margins anticipated upward of 71%, despite projected compression from rising commodity prices and foreign exchange. Chronologically, in the Sep'25 Qtr concall, FY26 EBITDA margin was guided at 25% to 26% (expected at the lower end). This FY26 guidance was reaffirmed during the Dec'25 Qtr concall, with 9M FY26 adjusted EBITDA margin standing at 24.9%. In the Jun'26 Qtr concall, management reaffirmed its FY27 EBITDA margin guidance of 25.5% to 26.5%. For the Jun'26 Qtr, Quarterly Financial Results reported an actual EBITDA margin of 26.2% and EBITDA of INR 1,056 crore.
5 more themes on the ELITE plan.